Exelixis (EXEL) financials

Biotechnology · NASDAQ · Health Care

$69.39 +4.82% Close Oct 30, 2026 Live

Exelixis revenue and earnings by year

Exelixis's revenue was $2.32 billion in the fiscal year to January 2, 2026, up 7.0% from the year before. Net income was $783 million, 33.7% of revenue. Since the fiscal year to December 30, 2016, revenue has grown 31.9% a year on average.

RevenueNet income
$0$1.00B$2.00B
2016201720182019202020212022202320242025

Fiscal years, each labelled by the calendar year it ended in.

Income statement, the last 10 fiscal years

In billions of US dollars except per-share figures. Each column is a fiscal year, named by the month it ended.
Fiscal year toJan 2026Jan 2025Dec 2023Dec 2022Dec 2021Jan 2021Jan 2020Dec 2018Dec 2017Dec 2016
Revenue2.322.171.831.611.430.990.970.850.450.19
Revenue growth7.0%18.5%13.6%12.3%45.3%2.0%13.3%88.7%136.3%—
Gross profit2.242.091.761.551.380.950.930.830.440.18
Gross margin96.4%96.5%96.0%96.4%96.3%96.3%96.6%96.9%96.7%96.6%
Operating income0.870.600.170.200.290.110.370.440.17-0.03
Operating margin37.6%27.9%9.3%12.5%20.0%11.1%38.2%51.4%36.7%-14.7%
Net income0.780.520.210.180.230.110.320.690.15-0.07
Net margin33.7%24.0%11.4%11.3%16.1%11.3%33.2%80.8%34.1%-36.7%
Diluted EPS$2.78$1.76$0.65$0.56$0.72$0.35$1.02$2.21—-$0.28
Free cash flow0.880.670.290.330.350.180.510.380.140.21

Diluted EPS is stated in today's shares (adjusted for every split since). Quarterly statements and the income statement as a flow chart are in the app: open EXEL in Markets.

See also: EXEL valuation and P/E history · EXEL returns

No forecast, no recommendation. This page describes Exelixis from published data; it is not advice to buy, sell or hold any security.

Figures as of the close on Oct 30, 2026 unless a row says otherwise. Prices are split adjusted; returns include dividends reinvested. Data may be delayed. See the disclaimer and how TrendArc works.